Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic Radiotherapy and Durvalumab With or Without Tremelimumab or Olaparib in ES-SCLC
NCT03923270Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2019
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tremelimumab and olaparib in small cell lung cancer (SCLC) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Unacceptable Serious Adverse Events at 13 weeks and Progression Free Survival at 6 months. Started Jun 2019; status: active, not recruiting.
02
Drugs
tremelimumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03923270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923270.